These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3463556)

  • 1. Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.
    Browning MJ; Holt HA; White LO; Chapman ST; Banks RA; Reeves DS; Yates RA
    J Antimicrob Chemother; 1986 Jul; 18(1):103-6. PubMed ID: 3463556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.
    Ohkawa M; Hirano S; Tokunaga S; Motoi I; Shoda R; Ikeda A; Sugata T; Sawaki M; Shimamura M; Okasho A; Kuroda K
    Antimicrob Agents Chemother; 1983 Jan; 23(1):31-5. PubMed ID: 6572490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ
    Nephron; 1986; 44(3):191-4. PubMed ID: 2431330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on abnormalities of ion transport in vivo in patients with chronic renal failure.
    Brearley CJ; Aronson JK; Boon NA; Raine AE
    Clin Sci (Lond); 1993 Dec; 85(6):725-31. PubMed ID: 8287666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotetan elimination in patients with varying degrees of renal dysfunction.
    Wright N; Wise R; Hegarty T
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():213-6. PubMed ID: 6573319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis.
    Lam YW; Flaherty JF; Yumena L; Schoenfeld PY; Gambertoglio JG
    J Antimicrob Chemother; 1995 Jul; 36(1):157-63. PubMed ID: 8537262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.
    Srinivasan S; Neu HC
    Antimicrob Agents Chemother; 1981 Sep; 20(3):398-400. PubMed ID: 6458236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxalactam pharmacokinetics during hemodialysis.
    Aronoff GR; Sloan RS; Mong SA; Luft FC; Kleit SA
    Antimicrob Agents Chemother; 1981 Apr; 19(4):575-7. PubMed ID: 6454386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis.
    Grech-Bélanger O; Langlois S; LeBoeuf E
    J Clin Pharmacol; 1988 May; 28(5):477-80. PubMed ID: 3392246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers.
    Guibert J; Kitzis MD; Yvelin C; Acar JF
    J Antimicrob Chemother; 1983 Jan; 11 Suppl():201-6. PubMed ID: 6573317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.
    Flouvat BL; Imbert C; Dubois DM; Temperville BP; Roux AF; Chevalier GC; Humbert G
    Br J Clin Pharmacol; 1983 Jun; 15(6):735-41. PubMed ID: 6871072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.
    Traina GL; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G; Bonati M
    Eur J Clin Pharmacol; 1986; 31(4):501-4. PubMed ID: 2949981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis.
    Shah GM; Winer RL; Krasny HC
    Am J Kidney Dis; 1986 Jun; 7(6):507-10. PubMed ID: 3717158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxalactam kinetics during chronic ambulatory peritoneal dialysis.
    Singlas E; Boutron HF; Merdjan H; Brocard JF; Pocheville M; Fries D
    Clin Pharmacol Ther; 1983 Sep; 34(3):403-7. PubMed ID: 6224624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal function and dialysis on temocillin pharmacokinetics.
    Boelaert J; Daneels R; Schurgers M; Mellows G; Swaisland AJ; Lambert AM; Van Landuyt HW
    Drugs; 1985; 29 Suppl 5():109-13. PubMed ID: 4029012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis.
    Veys N; Lameire N; Malerczyk V; Lehr KH; Rosenkranz B; Ringoir S
    Clin Pharmacol Ther; 1993 Oct; 54(4):395-401. PubMed ID: 8222482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.